gRED EVP Recognized for Seminal Advances in the Field
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that Richard Scheller, Ph.D., Executive Vice President, Research and Early Development (gRED), is a winner of the 2010 Kavli Prize in Neuroscience, awarded for outstanding achievement in advancing our knowledge and understanding of the brain and nervous system.
The Kavli Prizes, presented every two years in Oslo, Norway in cooperation with the Norwegian Academy of Science and Letters, recognize scientists for their seminal advances in the research areas of astrophysics, nanoscience and neuroscience. Dr. Scheller shares this year’s neuroscience prize, along with its cash award of one million dollars, with James Rothman, Professor and Chairman of Cell Biology at Yale University, and Thomas Sudhof, Professor of Molecular and Cellular Physiology at Stanford University. Dr. Scheller is donating his proceeds from the award to the Wildlife Conservation Network, http://www.wildnet.org, a San Francisco Bay Area-based organization dedicated to protecting endangered species and preserving their natural habitats.
Dr. Scheller is a member of Genentech’s executive committee and the Enlarged Roche Corporate Executive Committee. He is responsible for overseeing the strategy for Genentech’s research, drug discovery, business development and early development activities. Prior to joining Genentech in 2001, Dr. Scheller was Professor of Molecular and Cellular Physiology and Biological Science at Stanford University and an investigator with the Howard Hughes Medical Institute.
Dr. Scheller has published more than 200 papers in peer-reviewed scientific journals. He is a member of the Academy of Arts and Sciences and the National Academy of Sciences. Scheller received his Bachelor of Science in biochemistry at the University of Wisconsin, Madison, where he received the Distinguished Alumni Award in 2009. He was awarded his doctorate in chemistry from the California Institute of Technology. He was a postdoctoral fellow at both the California Institute of Technology and Columbia University.
Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a wholly owned member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
Robin Snyder, 650-467-6800
KEYWORDS: United States Europe North America Norway California
INDUSTRY KEYWORDS: Seniors Women Health Biotechnology Cardiology Clinical Trials Oncology Optical Pharmaceutical Consumer